IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
San Miguel, Jesus F.1; Schlag, Rudolf2; Khuageva, Nuriet K.3; Dimopoulos, Meletios Athanasios4; Shpilberg, Ofer5; Kropff, Martin6; Spicka, Ivan7; Petrucci, Maria T.8; Palumbo, Antonio9; Samoilova, Olga S.10; Dmoszynska, Anna11; Abdulkadyrov, Kudrat M.12; Delforge, Michel13; Jiang, Bin14; Mateos, Maria-Victoria1; Anderson, Kenneth C.; Esseltine, Dixie-Lee16; Liu, Kevin17; Deraedt, William M.18; Cakana, Andrew Z.19; van de Velde, Helgi18; Richardson, Paul G.15
刊名BLOOD
2011-11-18
118期:21页:221-222
收录类别SCI ; ISTP
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
语种英语
WOS记录号WOS:000299597100477
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56547
专题北京大学第二临床医学院_血液科
作者单位1.Janssen Res & Dev, High Wycombe, Bucks, England
2.Praxisklin Dr Schlag, Wurzburg, Germany
3.SP Botkin Moscow City Clin Hosp, Moscow, Russia
4.Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel
5.Univ Munster, Munster, Germany
6.Charles Univ Prague, Prague, Czech Republic
7.Univ Roma La Sapienza, Rome, Italy
8.Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium
9.Janssen Res & Dev, Raritan, NJ USA
10.Janssen Res & Dev, Beerse, Belgium
11.Nizhnii Novgorod Reg Clin Hosp, Novgorod, Russia
12.Med Univ Lublin, Lublin, Poland
13.St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia
14.Hosp Clin Univ, Salamanca, Spain
15.Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece
16.Univ Turin, Div Hematol, Myeloma Unit, AOU S Giovanni Battista, Turin, Italy
17.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China
18.Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
19.Millennium Pharmaceut Inc, Cambridge, MA USA
推荐引用方式
GB/T 7714
San Miguel, Jesus F.,Schlag, Rudolf,Khuageva, Nuriet K.,et al. Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial[J]. BLOOD,2011,118(21):221-222.
APA San Miguel, Jesus F..,Schlag, Rudolf.,Khuageva, Nuriet K..,Dimopoulos, Meletios Athanasios.,Shpilberg, Ofer.,...&Richardson, Paul G..(2011).Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial.BLOOD,118(21),221-222.
MLA San Miguel, Jesus F.,et al."Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial".BLOOD 118.21(2011):221-222.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[San Miguel, Jesus F.]的文章
[Schlag, Rudolf]的文章
[Khuageva, Nuriet K.]的文章
百度学术
百度学术中相似的文章
[San Miguel, Jesus F.]的文章
[Schlag, Rudolf]的文章
[Khuageva, Nuriet K.]的文章
必应学术
必应学术中相似的文章
[San Miguel, Jesus F.]的文章
[Schlag, Rudolf]的文章
[Khuageva, Nuriet K.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。